{
    "address": "Virdings Alle 2",
    "city": "Uppsala",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W5152K105",
    "description": "Klaria Pharma Holding AB engages in the development and commercialization of pharmaceutical products for migraine and cancer-related pain. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-10-21. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The firm operates Klaria Pharma AB as a wholly owned subsidiary.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Pharmaceuticals",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Pharmaceuticals",
    "gsector": "Health Care",
    "gsubind": "Pharmaceuticals",
    "ipo": "2015-10-21",
    "isin": "SE0007280326",
    "logo": "https://finnhub.io/api/logo?symbol=KLAR.ST",
    "marketCapitalization": 401.5142,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Klaria Pharma Holding AB (publ)",
    "phone": "4684464299.0",
    "sedol": "BYX1Y38",
    "shareOutstanding": 51.808279,
    "state": "UPPSALA",
    "ticker": "KLAR.ST",
    "weburl": "http://www.klaria.com/"
}